Literature DB >> 16695918

Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure.

F L Lieberman1, T B Reynolds.   

Abstract

Plasma volume was measured by using albumin-(131)I- and (51)Cr-labeled erythrocytes in 24 control subjects, 140 patients with hepatic cirrhosis, and 10 patients with various portal-systemic shunts for the relief of noncirrhotic portal hypertension. The cirrhotic patients included subgroups with ascites, functional renal failure, and portacaval anastomoses. Elevated values for plasma volume, by both methods, were found in each group of patients.The lymph space drained by the thoracic duct was measured by a radioisotopic technique in six patients with cirrhosis and ascites. The amount of radioactivity in this space was found to be negligible in accounting for the elevated plasma volume. Similar results were obtained when the degree of leakage of albumin-(131)I into the ascites was determined in 10 patients with cirrhosis.The plasma volume was unusually elevated in patients who had bled from esophageal varices, and paired comparisons before and after portacaval shunt normal values. There was a statistically significant correlation between normal values. There was a statistically significant correlation between plasma volume and wedged hepatic venous pressure measured in 36 patients.We concluded that the elevated values for plasma volume in cirrhosis are valid and are not artifacts due to leakage of albumin-(131)I from the circulation during mixing. We also concluded that portal hypertension is responsible for the plasma volume expansion; however, we were unable on this basis to explain the failure of portacaval shunting to return the plasma volume to normal, unless the shunt or some other factor keeps the plasma volume elevated.

Entities:  

Year:  1967        PMID: 16695918      PMCID: PMC297131          DOI: 10.1172/JCI105622

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Further observations on the distribution of red cells and plasma in disease; the low body haematocrit: venous haematocrit ratio.

Authors:  A HOPE; D VEREL
Journal:  Clin Sci       Date:  1955-08       Impact factor: 6.124

2.  The hematocrit of capillary blood.

Authors:  J J McGOVERN; A R JONES; A G STEINBERG
Journal:  N Engl J Med       Date:  1955-08-25       Impact factor: 91.245

3.  Blood volume in patients with Laennec's cirrhosis of the liver as determined by radioactive chromium-tagged red cells.

Authors:  S EISENBERG
Journal:  Am J Med       Date:  1956-02       Impact factor: 4.965

4.  Ascitic fluid and plasma protein exchange in cirrhosis of the liver; studies with radioiodinated human serum albumin and gamma globulin.

Authors:  F K BAUER; W H BLAHD; M FIELDS; G GETCHELL
Journal:  Metabolism       Date:  1954-07       Impact factor: 8.694

5.  The circulating splanchnic blood volume in dog and man.

Authors:  S E BRADLEY; P A MARKS; P C REYNELL; J MELTZER
Journal:  Trans Assoc Am Physicians       Date:  1953

6.  Hepatic cirrhosis: effect of sodium chloride administration and restriction and of abdominal paracentesis on electrolyte and water balance.

Authors:  G J GABUZDA; H S TRAEGER; C S DAVIDSON
Journal:  J Clin Invest       Date:  1954-05       Impact factor: 14.808

7.  Studies of red-cell volume and turnover using radiochromium; description of a new closed method of red-cell volume measurement.

Authors:  R C READ
Journal:  N Engl J Med       Date:  1954-06-17       Impact factor: 91.245

8.  The body/venous hematocrit ratio: its constancy over a wide hematocrit range.

Authors:  H CHAPLIN; P L MOLLISON; H VETTER
Journal:  J Clin Invest       Date:  1953-12       Impact factor: 14.808

9.  Investigation of the permeability factor in ascites and edema using albumin tagged with I 131.

Authors:  J A SHOENBERGER; G KROLL; A SAKAMOTO; R M KARK
Journal:  Gastroenterology       Date:  1952-12       Impact factor: 22.682

10.  Blood volume in health and disease.

Authors:  S A BERSON
Journal:  Bull N Y Acad Med       Date:  1954-10
View more
  44 in total

1.  Effect of portal-systemic anastomosis on renal haemodynamics in cirrhosis.

Authors:  H Ring-Larsen; B Hesse; B Stigsby
Journal:  Gut       Date:  1976-11       Impact factor: 23.059

Review 2.  The endocrinology and pathophysiology of alcoholic cirrhosis and functional renal failure--a review.

Authors:  E S Domurat; A N Elias
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

3.  A rational approach to the treatment of ascites.

Authors:  V Arroyo; J Rodés
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

4.  Natriuretic hormone--its possible role in fluid and electrolyte disturbances in chronic liver disease.

Authors:  H J Kramer
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

5.  Effect of meal induced splanchnic arterial vasodilatation on renal arterial haemodynamics in normal subjects and patients with cirrhosis.

Authors:  T Iwao; K Oho; R Nakano; M Yamawaki; T Sakai; M Sato; Y Miyamoto; A Toyonaga; K Tanikawa
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

6.  Intravascular volume in cirrhosis. Reassessment using improved methodology.

Authors:  W G Rector; F Ibarra
Journal:  Dig Dis Sci       Date:  1988-04       Impact factor: 3.199

7.  Systemic hemodynamics in non-cirrhotic portal hypertension--a clinical study of 19 patients.

Authors:  A Harada; T Nonami; Y Kasai; A Nakao; H Takagi
Journal:  Jpn J Surg       Date:  1988-11

8.  The hepatorenal syndrome.

Authors:  M Pinzani; R D Zipser
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

Review 9.  Renal changes in cirrhosis.

Authors:  M Kew
Journal:  Gut       Date:  1972-09       Impact factor: 23.059

10.  Blood group lewis phenotype on erythrocytes and in saliva in alcoholic pancreatitis and chronic liver disease.

Authors:  L Stigendal; R Olsson; L Rydberg; B E Samuelsson
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.